Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Improved detection methods could make a world of difference for patients undergoing cancer therapy.
A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.
Zynlonta led to complete remission in nearly a quarter of patients with large B-cell lymphoma.
After a median follow-up of 13 months, four of the five patients had ongoing complete remission.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
A former labor and delivery nurse, Lindy Sledge, 62, lives with her family in Franklin, Kentucky. She has mantle cell lymphoma.
Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.
A dedicated student of jiujitsu, Avie Barron, 36, was diagnosed with non-Hodgkin lymphoma in her right lung.
More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.
Tecartus led to durable remission in a majority of participants in a Phase II study.
The popular weed killer has been linked to tens of thousands of cases of non–Hodgkin lymphoma.
The SADAL study showed a 29% response rate for treatment-experienced people with DLBCL.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.